NASDAQ:OLMA

Olema Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy OLMA

*Your capital is at risk

$11.45

-0.370 (-3.13%)

At Close: Jul 31, 2026

Olema Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -49.61. In total, the insiders bought 3.92M and sold 1.28M OLMA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-49.61
● Buy	3.92M shares
● Sell	1.28M shares
62% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jun 18, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -49.61. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 12, 2026 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	10 000 Value: $283.4K
Dec 26, 2025 Sell	Common Stock G-Gift	Bohen Sean President And CEO	CEO / President	8 500 Value: $0
Dec 23, 2025 Sell	Common Stock S-Sale	Zojwalla Naseem Chief Medical Officer	Officer	99 509 Value: $2.75M
Dec 23, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	50 000 Value: $351.0K
Dec 23, 2025 Buy	Common Stock M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	50 000 Value: $351.0K
Dec 22, 2025 Sell	Common Stock S-Sale	Harmon Cyrus Director	Director	2 881 Value: $82.2K
Dec 22, 2025 Sell	Common Stock S-Sale	Zojwalla Naseem Chief Medical Officer	Officer	100 000 Value: $2.80M
Dec 22, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	7 182 Value: $50.4K
Dec 22, 2025 Buy	Common Stock M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	7 182 Value: $50.4K
Dec 22, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	42 818 Value: $653.0K
Dec 22, 2025 Buy	Common Stock M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	42 818 Value: $653.0K
Dec 19, 2025 Sell	Common Stock S-Sale	Zojwalla Naseem Chief Medical Officer	Officer	12 921 Value: $373.8K
Dec 19, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	40 000 Value: $610.0K
Dec 19, 2025 Buy	Common Stock M-Exempt	Zojwalla Naseem Chief Medical Officer	Officer	40 000 Value: $610.0K
Dec 19, 2025 Sell	Common Stock G-Gift	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	9 000 Value: $0
Dec 19, 2025 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	6 046 Value: $189.8K
Dec 19, 2025 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	1 225 Value: $34.4K
Dec 19, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Clark Ian T Director	Director	21 520 Value: $77.7K
Dec 19, 2025 Sell	Common Stock S-Sale	Clark Ian T Director	Director	41 840 Value: $1.28M
Dec 19, 2025 Sell	Common Stock S-Sale	Clark Ian T Director	Director	193 056 Value: $5.74M
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	21 520 Value: $77.7K
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	21 520 Value: $168.7K
Dec 19, 2025 Buy	Common Stock M-Exempt	Clark Ian T Director	Director	12 070 Value: $49.2K
Dec 19, 2025 Sell	Common Stock S-Sale	Clark Ian T Director	Director	29 904 Value: $862.1K
Dec 19, 2025 Sell	Common Stock S-Sale	Zojwalla Naseem Chief Medical Officer	Officer	57 079 Value: $1.60M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...

Read Full Profile Here